Maxcyte annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Maxcyte Depreciation & Amortization Growth & History (MXCT)
Maxcyte's depreciation and amortization was $4.3M for fiscal 2025.
View full Maxcyte company overviewMaxcyte annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.3M | $25,000 | +0.58% |
| 2024 | 2024-12-31 | $4.3M | $144,000 | +3.45% |
| 2023 | 2023-12-31 | $4.2M | $1.5M | +54.60% |
| 2022 | 2022-12-31 | $2.7M | $1.3M | +89.48% |
| 2021 | 2021-12-31 | $1.4M | $376,200 | +35.91% |
| 2020 | 2020-12-31 | $1.0M | $434,200 | +70.77% |
| 2019 | 2019-12-31 | $613,500 | — | — |
Maxcyte quarterly depreciation and amortization
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $953,000 | −$127,000 | −11.76% |
| Q1 2026 | 2026-03-31 | $1.0M | −$49,000 | −4.47% |
| Q4 2025 | 2025-12-31 | $1.9M | — | — |
| Q3 2025 | 2025-09-30 | $1.0M | −$22,000 | −2.06% |
| Q2 2025 | 2025-06-30 | $1.1M | −$1,000 | −0.09% |
| Q1 2025 | 2025-03-31 | $1.1M | −$15,000 | −1.35% |
| Q3 2024 | 2024-09-30 | $1.1M | −$15,000 | −1.39% |
| Q2 2024 | 2024-06-30 | $1.1M | $55,000 | +5.36% |
| Q1 2024 | 2024-03-31 | $1.1M | $149,000 | +15.49% |
| Q3 2023 | 2023-09-30 | $1.1M | $337,700 | +45.43% |
| Q2 2023 | 2023-06-30 | $1.0M | $478,600 | +87.43% |
| Q1 2023 | 2023-03-31 | $962,000 | $474,600 | +97.37% |
| Q3 2022 | 2022-09-30 | $743,300 | $377,300 | +103.09% |
| Q2 2022 | 2022-06-30 | $547,400 | $222,400 | +68.43% |
| Q1 2022 | 2022-03-31 | $487,400 | $171,500 | +54.29% |
| Q3 2021 | 2021-09-30 | $366,000 | $75,700 | +26.08% |
| Q2 2021 | 2021-06-30 | $325,000 | $68,500 | +26.71% |
| Q1 2021 | 2021-03-31 | $315,900 | — | — |
| Q3 2020 | 2020-09-30 | $290,300 | — | — |
| Q2 2020 | 2020-06-30 | $256,500 | — | — |
Maxcyte depreciation and amortization trends
Over the last five fiscal years, Maxcyte's depreciation and amortization increased from $1.0M to $4.3M, a change of $3.3M. The latest reported quarter, Q2 2026, shows $953,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Maxcyte source filings ↗